Tavolixizumab

View Clinical trials for Tavolixizumab Get Tavolixizumab Patent Info for Free

NCI: An agonistic, humanized monoclonal antibody against receptor OX40 (CD134), with potential immunostimulatory activity. Upon administration, anti-OX40 monoclonal antibody MEDI0562 selectively binds to and activates the OX40 receptor. OX40 receptor activation induces proliferation of memory and effector T-lymphocytes. In the presence of tumor-associated antigens (TAAs), this agent may promote an immune response against TAAs-expressing tumor cells. OX40, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) receptor family, is expressed on T-lymphocytes and provides a co-stimulatory signal for the proliferation and survival of activated T-cells.

Inn NameTavolixizumab
Lab CodesMEDI-0562
Chemical NameImmunoglobulin G1-kappa, anti-[Homo sapiensTNFRSF4 (tumor necrosis factor receptor (TNFR) superfamily member 4, OX40, CD134)], humanized and chimeric monoclonal antibody; gamma1 heavy chain (1-451) [chimeric VH (Mus musculus IGHV3-8*02 -(IGHD)-Homo sapiens IGHJ4*01) [8.7.15] (1-121) -Homo sapiens IGHG1*03, G1m3 (CH1 (122-219),hinge (220-234), CH2 (235 344), CH3 (345-449), CHS (450-451)) (122-451)], (224-214')-disulfide with kappa light chain (1’-214’) [humanized V-KAPPA (Homo sapiens IGKV1-39*01 (88.40%) -IGKJ1*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 (108'-214')]; dimer (230-230":233- 233")-bisdisulfide
SequenceHeavy chain
QVQLQESGPG LVKPSQTLSL TCAVYGGSFS SGYWNWIRKH PGKGLEYIGY 50
ISYNGITYHN PSLKSRITIN RDTSKNQYSL QLNSVTPEDT AVYYCARYKY 100
DYDGGHAMDY WGQGTLVTVS SASTKGPSVF PLAPSSKSTS GGTAALGCLV 150
KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ 200
TYICNVNHKP SNTKVDKRVE PKSCDKTHTC PPCPAPELLG GPSVFLFPPK 250
PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY 300
NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP 350
QVYTLPPSRE EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP 400
VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG 450
K 451

Light chain
DIQMTQSPSS LSASVGDRVT ITCRASQDIS NYLNWYQQKP GKAPKLLIYY 50
TSKLHSGVPS RFSGSGSGTD YTLTISSLQP EDFATYYCQQ GSALPWTFGQ 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC 214

Disulfide bridges location
Intra-H (C23-C104) 22-95 148-204 265-325 371-429
22''-95'' 148''-204'' 265''-325'' 371''-429''
Intra-L (C23-C104) 23'-88' 134'-194'
23'''-88''' 134'''-194'''
Inter-H-L (h 5-CL 126) 224-214' 224''-214'''
Inter-H-H (h 11, h 14) 230-230'' 233-233''

N-glycosylation sites
H CH2 N84.4:
301, 301''
Fucosylated complex bi-antennary CHO-type glycans
Chemical StructureTavolixizumab.png
Cas Registry Number1635395-25-3
New Molecular EntityYes
OriginatorMedImmune
DeveloperAstraZeneca
Mechanism Of ActionOX40 receptor agonist
Who Atc CodesL01X-C (Monoclonal antibodies)
Ephmra CodesL1G (Monoclonal Antibody Antineoplastics)
IndicationAdvanced Solid Tumors

Free counters!